Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2024-09-27 Major Shareholding Noti…
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is the standard regulatory filing used in the UK to disclose changes in significant share ownership (crossing thresholds). It identifies BlackRock, Inc. as the person subject to the notification obligation regarding their holdings in MaxCyte, Inc. This fits the definition of a Major Shareholding Notification (MRQ).
2024-09-27 English
Regulatory Filings 2024
Regulatory Filings
2024-09-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is the standard regulatory filing used in the UK to disclose when a shareholder's interest in a company crosses specific voting rights thresholds. The document explicitly identifies BlackRock, Inc. as the entity subject to the notification obligation regarding its holdings in MaxCyte, Inc. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2024-09-20 English
Director's Dealing 2024
Director's Dealing
2024-09-18 English
Director's Dealing 2024
Director's Dealing
2024-09-18 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is a standard regulatory filing used in the UK to disclose significant changes in share ownership (crossing thresholds). This document explicitly details the voting rights held by BlackRock, Inc. in MaxCyte, Inc. and follows the standard TR-1 template required by the Financial Conduct Authority (FCA). As it pertains to the notification of major shareholding levels, it falls under the 'Major Shareholding Notification' category.
2024-09-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.